Oncocyte's VitaGraft Kidney test receives Medicare coverage decision from Palmetto GBA

Insight Molecular Diagnostics Inc.

Palmetto GBA, a Medicare Administrative Contractor, issued final LCD for VitaGraft Kidney test.
Test meets coverage criteria under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).
Decision could enable Medicare reimbursement for Oncocyte's transplant rejection test.
Coverage applies to beneficiaries under Palmetto GBA's jurisdiction.
Oncocyte announced the decision in an August 28, 2023 press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.